Company intelligence / Profile preview

Violet Therapeutics

Cambridge, Massachusetts, United Statesviolettx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Violet Therapeutics has developed proprietary platforms to map the cellular connectome at scale. Their lead program targets neuroinflammation in multiple neurodegenerative indications, with a particular focus on Alzheimer’s disease. The company remains pre-clinical as of 2023 and has raised significant seed funding to advance its programs

Therapeutic areas: OncologyImmunologyNeurology
Modalities: First-in-class drug discovery platforms
Industry: Biotech

Drug pipeline

1 asset

VTT-001

Preclinical

Partnerships

Dementia Discovery Fund (DDF)UTEC/University of Tokyo Edge Capital PartnersMass General Brigham VenturesOno Venture Investment

Beyond the preview

Go deeper on Violet Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Violet Therapeutics.

Explore the full profile